<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: This double-blind study evaluated the efficacy and safety of <z:chebi fb="0" ids="6801">metformin</z:chebi>-<z:chebi fb="0" ids="5441">glibenclamide</z:chebi> tablets vs. <z:chebi fb="0" ids="6801">metformin</z:chebi> plus <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> therapy in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> inadequately controlled on <z:chebi fb="0" ids="6801">metformin</z:chebi> monotherapy </plain></SENT>
<SENT sid="1" pm="."><plain>SUBJECTS AND METHODS: After an open-label, <z:chebi fb="0" ids="6801">metformin</z:chebi> lead-in phase, 318 patients were randomly assigned to treatment based on <z:chebi fb="0" ids="6801">metformin</z:chebi>-<z:chebi fb="0" ids="5441">glibenclamide</z:chebi> 500/2.5 mg tablets (initial daily dose 1000/5 mg) or <z:chebi fb="0" ids="6801">metformin</z:chebi> 500 mg plus <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> 4 mg (initial daily dose 1000-2000 mg + 4 mg, depending on previous treatment) for 24 weeks </plain></SENT>
<SENT sid="2" pm="."><plain>Doses were titrated to achieve the therapeutic glycaemic target </plain></SENT>
<SENT sid="3" pm="."><plain>The primary efficacy variable was the change in HbA1C </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: At week 24, <z:chebi fb="0" ids="6801">metformin</z:chebi>-<z:chebi fb="0" ids="5441">glibenclamide</z:chebi> tablets resulted in significantly greater reductions in HbA1C (-1.5%) and fasting plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> [-2.6 mmol/l (-46 mg/dl)] than <z:chebi fb="0" ids="6801">metformin</z:chebi> plus <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> [-1.1%, p &lt; 0.001; -2 mmol/l (-36 mg/dl), p = 0.03] </plain></SENT>
<SENT sid="5" pm="."><plain>More patients receiving <z:chebi fb="0" ids="6801">metformin</z:chebi>-<z:chebi fb="0" ids="5441">glibenclamide</z:chebi> attained HbA1C &lt;7.0% than did those in the <z:chebi fb="0" ids="6801">metformin</z:chebi> plus <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> group (60 vs. 47%) and had fasting plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> levels &lt;7 mmol/l (&lt;126 mg/dl) by week 24 (34 vs. 25%) </plain></SENT>
<SENT sid="6" pm="."><plain>Both treatments were well tolerated </plain></SENT>
<SENT sid="7" pm="."><plain>Frequency of adverse gastrointestinal events was comparable between groups </plain></SENT>
<SENT sid="8" pm="."><plain>Four per cent of patients receiving <z:chebi fb="0" ids="6801">metformin</z:chebi>-<z:chebi fb="0" ids="5441">glibenclamide</z:chebi> withdrew because of symptomatic <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> contrasted with 3% of patients receiving <z:chebi fb="0" ids="6801">metformin</z:chebi> plus <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> who withdrew because of persistent <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>Hypoglycaemic events were mild or moderate in intensity and were easily self-managed </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: <z:chebi fb="0" ids="6801">Metformin</z:chebi>-<z:chebi fb="0" ids="5441">glibenclamide</z:chebi> tablets resulted in significantly greater reductions in HbA1C and fasting plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> compared with <z:chebi fb="0" ids="6801">metformin</z:chebi> plus <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> inadequately controlled on <z:chebi fb="0" ids="6801">metformin</z:chebi> monotherapy </plain></SENT>
</text></document>